StockNews.com downgraded shares of iCAD (NASDAQ:ICAD – Free Report) from a hold rating to a sell rating in a report issued on Wednesday morning.
iCAD Stock Down 8.1 %
Shares of iCAD stock opened at $1.64 on Wednesday. iCAD has a 52-week low of $1.18 and a 52-week high of $2.65. The company has a fifty day moving average of $1.71 and a 200-day moving average of $1.54.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Virtu Financial LLC grew its position in iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after acquiring an additional 7,604 shares during the last quarter. Perritt Capital Management Inc. boosted its stake in shares of iCAD by 7.5% during the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after purchasing an additional 9,717 shares during the period. Perritt Capital Management Inc grew its holdings in shares of iCAD by 14.2% in the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after purchasing an additional 19,917 shares during the last quarter. First Eagle Investment Management LLC grew its holdings in shares of iCAD by 3.2% in the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Essex LLC purchased a new position in shares of iCAD in the third quarter worth $216,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
- Five stocks we like better than iCAD
- What is the Dow Jones Industrial Average (DJIA)?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- When to Sell a Stock for Profit or Loss
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- P/E Ratio Calculation: How to Assess Stocks
- Time to Load Up on Home Builders?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
